CRANFORD, N.J., March 31, 2026
Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its LYMPHIR™ (denileukin diftitox-cxdl) therapy, highlighting rapid institutional adoption, expanding payer coverage, and advancing clinical development programs. The update underscores the company’s growing footprint in the cutaneous T-cell lymphoma (CTCL) treatment landscape, with early indicators pointing toward sustained commercial traction and broader integration into oncology practice.
Launched in December 2025 after receiving U.S. Food and Drug Administration (FDA) approval, LYMPHIR is designed for adult patients with relapsed or refractory Stage I–III CTCL who have received prior systemic therapy. The therapy’s unique mechanism as an IL-2 receptor-directed cytotoxin positions it as a differentiated immunotherapy option, addressing a market with significant unmet medical needs.
Strong Commercial Uptake and Market Access Expansion
Citius Oncology reported robust early adoption across leading cancer centers, with approximately 83% of targeted institutions either completing or progressing through formulary inclusion. This rapid uptake is further supported by sequential growth in orders and increasing repeat prescriptions, signaling strong physician confidence and early clinical success.
Market access has also expanded significantly, with around 135 health plans covering nearly 80% of insured lives now providing reimbursement support. Notably, no reimbursement denials or prior authorization barriers have been reported, a critical factor in accelerating patient access and driving prescription growth.
Advertisement
The company is also expanding its reach beyond major oncology centers into community infusion settings, enabling broader patient access and supporting the transition of care closer to home. Ongoing commercial execution—including field team expansion, medical education initiatives, and digital engagement strategies—is expected to further strengthen LYMPHIR’s market penetration in the coming months. These efforts collectively establish a strong foundation for sustained revenue growth and long-term market leadership.
Innovative Mechanism and Clinical Differentiation
LYMPHIR’s mechanism of action combines the interleukin-2 (IL-2) receptor binding domain with diphtheria toxin fragments, enabling targeted destruction of cancer cells expressing IL-2 receptors. This approach not only induces direct cytotoxicity in tumor cells but also helps deplete immunosuppressive regulatory T cells (Tregs), enhancing the body’s anti-tumor immune response.
This dual mechanism provides a compelling therapeutic advantage, particularly in CTCL, where immune dysregulation plays a central role in disease progression. The therapy has already demonstrated clinically meaningful activity in relapsed or refractory patients, reinforcing its value as a new treatment option in a historically underserved segment..
Despite its clinical benefits, the therapy carries important safety considerations, including capillary leak syndrome, infusion-related reactions, and hepatotoxicity, which require careful monitoring. However, established management protocols and physician familiarity with immunotherapy safety profiles are expected to support safe and effective clinical use.
Expanding Clinical Development and Future Growth Strategy
Beyond its initial indication, Citius Oncology is actively exploring LYMPHIR’s potential in broader oncology applications through investigator-led clinical studies. At leading academic institutions, ongoing trials are evaluating the therapy in combination with checkpoint inhibitors such as pembrolizumab and as a pre-conditioning regimen prior to CAR-T therapy in aggressive lymphomas. Early topline data from these studies have shown promising results, supporting further development.
These efforts align with the company’s long-term vision to position LYMPHIR as a versatile immuno-oncology platform with combination therapy potential across multiple cancer types. International expansion is also underway, with distribution agreements in Europe and the Middle East, further extending the therapy’s global reach.
With a growing addressable market estimated to exceed $400 million and increasing demand for innovative immunotherapies, Citius Oncology is well-positioned to capitalize on LYMPHIR’s early success. The combination of strong commercial execution, expanding clinical evidence, and strategic global initiatives underscores the company’s commitment to advancing cancer care.
As LYMPHIR continues to gain traction in clinical practice, it represents a significant step forward in the treatment of CTCL, offering new hope for patients while reinforcing Citius Oncology’s leadership in targeted immunotherapy innovation.
Source: Citius Oncology press release
